Daxor Corporation

DXR

US2394671034

Closed End Funds

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9.65 ^USD	-2.92%		-1.03%	+0.52%

Apr. 16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
Apr. 10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023

August 28, 2023 at 04:01 pm EDT

Daxor Corporation reported earnings results for the half year ended June 30, 2023. For the half year, the company reported revenue was USD 0.080973 million. Net loss was USD 3.04 million.

Latest news about Daxor Corporation

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	Apr. 16	CI
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	Apr. 10	CI
Transcript : Daxor Corporation, 2023 Earnings Call, Mar 25, 2024	Mar. 25
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	Mar. 25	MT
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.	Mar. 24	CI
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	Mar. 11	CI
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	Mar. 08	CI
Daxor Corporation Announces Two Significant New Customer Transactions with Daxor's BVA-100 in January 2024	Feb. 12	CI
Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer	Jan. 02	CI
Certain Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 19-NOV-2023.	Nov. 18	CI
Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers	Nov. 13	CI
Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting	23-10-11	CI
Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Certain Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 21-AUG-2023.	23-08-20	CI
JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®	23-08-10	CI
Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy	23-07-12	CI
Daxor Says its Blood Volume Analysis Test Picked Up by Five US Hospitals	23-07-11	MT
Daxor Corporation Announces Further Acquisitions and Increased Utilization of Its Bva 100(R) Blood Volume Diagnostic Throughout the U.S	23-07-11	CI
Daxor Gets $1.1 Million Contract From US Defense Health Agency	23-07-05	MT
Daxor Announces Partial Exercise of Over-Allotment Option in Secondary Offering	23-06-22	MT
Top Premarket Decliners	23-05-22	MT
Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients	23-03-23	CI
Daxor Prices $2 Million Common Stock Offering	22-11-15	MT
Wall Street Set to Open Sharply Higher on Lower-Than-Expected Wholesale Inflation	22-11-15	MT

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.

Sector

Closed End Funds

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.65 USD

Average target price

23.25 USD

Spread / Average Target

+140.93%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Closed End Funds

	1st Jan change	Capi.
DAXOR CORPORATION	+0.52%	46.38M
ARES CAPITAL CORPORATION	+3.74%	12.61B
PERSHING SQUARE HOLDINGS, LTD.	+5.50%	9.01B
FS KKR CAPITAL CORP.	-3.20%	5.41B
PIMCO DYNAMIC INCOME FUND	+5.63%	5.19B
SPROTT PHYSICAL URANIUM TRUST FUND	+2.44%	5.25B
SPROTT PHYSICAL SILVER TRUST	+14.36%	4.48B
SPROTT PHYSICAL GOLD AND SILVER TRUST	+16.67%	4.44B
MACQUARIE KOREA INFRASTRUCTURE FUND	+1.53%	4B
3I INFRASTRUCTURE PLC	+1.56%	3.75B

Closed End Funds